Viecuri Hospital
Venlo, Netherlands
NCT Number: NCT03775499
The aim of the study is to confirm/prove safety of the probiotic and production of serpin in humans.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Venlo, Netherlands
This trial is a multicenter, double blind, randomized, placebo controlled, 2 by 2 cross-over design (i.e. 2-sequences, 2-periods, 2-treatments) for each specific population (i.e. self-reported Non Coeliac Gluten Sensitivity and Coeliac Disease subjects).
1 capsule of BL NCC 2705 or placebo will be given twice a day in the morning and in the evening with a meal over 2 periods of 4 days.
On day four a single dose of gluten (3g) will be administered and duodenal fluid will be collected in the following hours through a naso-intestinal catheter. The viability of BL NCC 2705, the production of serpin and its effects on gluten digestion and intestinal enzymatic activity will be determined.
No chronic administration of gluten as a challenge is foreseen in the study.
After a wash out period of minimum 2 weeks, period will be repeated.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
Time frame: from Baseline to end of study (up to maximum 43 days)
incidence, type and severity of adverse event
Time frame: from Baseline to end of study (up to maximum 43 days)
Sum of visual analog scale for gastro-intestinal symptoms assessment (nausea, vomiting, diarrhea, audible bowel sound, flatulence and abdominal cramping symptoms are assessed). Each scale is from 0 (no symptom) to 100mm (maximum symptom). The maximum sum value is 600.
Time frame: 19 sampling over 6h50 hours at visit 2 (day 4) and visit 3 (from day 22 to day 36)
Measurements via RT-PRC and immuno-assay
Time frame: 19 sampling over 6h50 hours at visit 2 (day 4) and visit 3 (from day 22 to day 36)
Measurements via PCR
Time frame: 10 sampling over 3h30 at visit 2 (day 4) and visit 3 (from day 22 to day 36)
Effect of BL NCC 2705 on gluten digestion based on the amount of gluten peptides detected in duodenal apsirates
Time frame: 10 sampling over 3h30 at visit 2 (day 4) and visit 3 (from day 22 to day 36)
Effect of BL NCC 2705 on gluten digestion based on the amount of gluten peptides detected in urine
Time frame: 19 sampling over 6h50 hours at visit 2 (day 4) and visit 3 (from day 22 to day 36)
Measurements of proteolytic activity based assay
Société des Produits Nestlé (SPN)
Industry
Proof of Concept Clinical Trial of Safety and Biological Activity of Bifidobacterium Longum NCC 2705 in Gluten Sensitivity
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02472704
Celiac Disease, Digestive System Diseases
View Trial DetailsNCT07063823
Celiac Disease, Digestive System Diseases
Stanford, California, United States
View Trial DetailsNCT07177287
Adults With Celiac Disease, Celiac Disease
Ankara, Turkey (Türkiye)
View Trial DetailsNCT05094232
Celiac Disease, Digestive System Diseases
Terrassa, Barcelona, Spain
View Trial Details